Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04806659
Other study ID # SHC016-I-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 4, 2020
Est. completion date December 31, 2023

Study information

Verified date March 2021
Source Nanjing Sanhome Pharmaceutical, Co., Ltd.
Contact Junmin Li, PhD
Phone 086-13817712211
Email drlijunmin@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of SH1573 in subjects with advanced relapsed, refractory acute myelogenous leukemia that harbor an IDH2 mutation.


Description:

SH1573 is an IDH2 mutation inhibitor. This is a phase 1, open-label, multicenter, single-arm study to evaluate safety, tolerability, PK, PD, and preliminary efficacy of SH1573 capsules in treatment of subjects with advanced relapsed, refractory acute myeloid leukemias (AML) that harbor an IDH2 mutation. The study consists of 2 parts: a dose-escalation part (Phase Ia) and a dose-expansion part (Phase Ib). The dose-escalation part will determine the MTD/R2PD. The dose-expansion part will administer the MTD/RP2D to subjects with mIDH2-positive AML.


Recruitment information / eligibility

Status Recruiting
Enrollment 41
Est. completion date December 31, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1.Subjects aged =18 years. - 2.Refractory or relapsed AML, or Untreated AML with age =70 years if not candidates for standard therapy. - 3.Subjects must have documented IDH2 mutaion by central testing. - 4.ECOG performance score of 0 to 2. - 5.Platelet count = 20,000/µL (transfusions allowed) unless due to underlying malignancy. - 6.AST, ALT = 3.0 x ULN unless due to underlying malignancy, and Serum total bilirubin = 1.5 x ULN unless due to Gilbert's disease, a gene mutation in UGT1A1, or leukemic organ involvement; Serum creatinine =1.5 x ULN or creatinine clearance > 40 mL/min based on the Cockroft-Gault formula. - 7.Female subjects with reproductive potential must have a negative serum pregnancy test within 72 hours prior to the start of therapy. Females of child-bearing potential and male patients should be willing to use barrier contraception during the study and until 6 months after completion of studyusing adequate contraceptive measures throughout the study. - 8.Never participate in other clinical trial in 1 month. - 9.Patients must sign and date written informed consent prior to admission to the study. Exclusion Criteria: - 1.Acute promyelocytic leukemia (APL). - 2.Secondary AML followed by chronic myeloid leukemia (CML). - 3.Subjects who previously received IDH2 mutation inhibitor. - 4. Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration. (Hydroxyurea is allowed for the control of peripheral leukemic blasts) - 5.Subjects who received an non-cytotoxic targeted drug <14 days or 5 half-lives prior to their first day of study drug administration. - 6.Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days of the first dose,or subjects on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). - 7.Subjects with any clinically relevant toxic effects of any prior treatment of cancer. (Subjects with residual Grade 1 toxicity are allowed with approval of the Medical Monitor.) - 8.Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. - 9.Subjects with uncontrolled severe infection that required anti-infective therapy. - 10.Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation. - 11.Any of the following cardiac criteria: 1. Active cardiac disease in 6 month before the first dose, such as New York Heart Association (NYHA) Class III or IV congestive heart failure, acute coronary syndrome or stroke. 2. Left ventricular ejection fraction (LVEF) = 40%. 3. Mean resting corrected QT interval (QTcF) > 470(female) or 450(male) msec. 4. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome. 5. Subjects taking medications that are known to prolong the QT interval unless discontinue at least 5 half-lives before the first dose of study drug. - 12. History of any other malignant tumor unless disease free survival = 1 year (except clinically cured cervical carcinoma in situ, basal cells or squamous epithelial skin cancer). - 13.Active infection with HIV, syphilis, hepatitis B or C. - 14.Subjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. - 15.Subjects with uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure > 100 mmHg) . - 16.Subjects taking the sensitive cytochrome P450 (CYP) substrate medications that have a narrow therapeutic range are excluded from the study unless they can be transferred to other medications within =5 half-lives prior to dosing: paclitaxel (CYP2C8) warfarin, phenytoin (CYP2C9), S-mephenytoin (CYP2C19); Subjects taking breast cancer resistant protein (BCRP) transporter, OATP1B1 or OATP1B3 sensitive substrates should be excluded from the study unless they can be transferred to other medications within = 5 half-lives prior to dosing. - 17.Any disease or conditionins would compromise the safety of the patient or interfere with study assessments in the opinion of the Investigator. - 18.female with breastfeeding. - 19.History of hypersensitivity to any active or inactive ingredient of SH1573. - 20.Subjects with any other conditions deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, or participate in the study participate in the study.

Study Design


Intervention

Drug:
SH1573 Capsules
Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.

Locations

Country Name City State
China Fujian Medical University Union Hospital Fuzhou Fujian
China Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 (28 days every cycle)and is at least possibly related to study drug. Up to 28 days after first dose of study drug
Primary Number of Participants With Adverse Events (AEs) The intensity of each AE was graded from 1 to 5 according to the NCI CTCAE Version 5.0. From the first dose of the study drug to 30 days after the last dose of study drug
Primary Rate of CR/CRh (complete remission with incomplete hematologic recovery) CR was defined as < 5% blasts in the bone marrow and full recovery of peripheral blood counts (platelets > 100 x 10^9/L and ANC > 1.0 x 10^9/L); CRh was defined as < 5% blasts in the bone marrow and partial recovery ofperipheral blood counts (platelets > 50 x 10^9/L and ANC > 0.5 x 10^9/L). From the first dose of study drug to the time of progressive disease, assessed up to 36 months
Secondary Overall Response Rate (ORR) ORR is defined as the percentage of participants achieving an overall response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML. From the first dose of study drug to the time of progressive disease, assessed up to 36 months.
Secondary Complete Response (CR) Rate CR was defined as < 5% blasts in the bone marrow and full recovery of peripheral blood counts (platelets > 100 x 10^9/L and ANC > 1.0 x 10^9/L). From the first dose of study drug to the time of progressive disease, assessed up to 36 months
Secondary Duration of Response(DOR) DOR was defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. From the first dose of study drug to the time of progressive disease, assessed up to 36 months
Secondary Overall Survival Overall survival was defined as the time from the date of first dose until death from any cause and was used to further assess the efficacy of SH1573. From the first dose of study drug to the end of study or death, assessed up to 36 months
Secondary Time to response (TTR) TTR is defined as the time from the date of first dose to the date of the first occurrence of response of CR, CRi, CRp, PR, or MLFS based on the 2003 revised IWG criteria for AML. From the first dose of study drug to the first response, assessed up to 36 months
Secondary Proportion of non-blood transfusion dependent subjects It is defined as the proportion of subjects who do not need blood transfusion for any sequential period =8 weeks during the study treatment period. From the first dose of study drug to last dose of study drug, assessed up to 36 months
Secondary Maximum serum drug concentration Blood samples will be obtained from all patients for determination of the maximum serum concentration of SH1573. 0, 1, 2, 4, 8, 12, 24, 48, 72 hours post-dose on single dose; 0 hour of cycle1 day 15; 0, 1, 2, 4, 8, 12, 24 hours post-dose on cycle 2 day 1; 0 hour of cycle 2 day 15 and cycle 3 day 1. Each cycle is 28 days.
Secondary Area under the concentration-time curve (AUC) Blood samples will be obtained from all patients for determination of AUC of SH1573. 0, 1, 2, 4, 8, 12, 24, 48, 72 hours post-dose on single dose; 0 hour of cycle1 day 15; 0, 1, 2, 4, 8, 12, 24 hours post-dose on cycle 2 day 1; 0 hour of cycle 2 day 15 and cycle 3 day 1. Each cycle is 28 days.
Secondary a-Hydroxyglutaric acid (2-HG) Plasma 2-HG was measured using qualified LC-MS/MS in order to characterize the pharmacodynamic (PD) effects of SH1573. 0, 24, 48 hours post-dose on single dose; Day1, Day15 pre-dose on cycle 1 and cycle 2; Day 1 pre-dose on cycle 3 and every 2 cycles afterwards. Each cycle is 28 days.
See also
  Status Clinical Trial Phase
Completed NCT01200355 - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Phase 4
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT01681537 - Lenalidomide Plus Chemotherapy for AML Phase 1
Completed NCT01385423 - Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) Phase 1
Terminated NCT01193400 - Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years Phase 2
Completed NCT00981240 - Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes Phase 1
Completed NCT00995332 - Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine Phase 1/Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00726934 - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients N/A
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT01031498 - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Phase 2
Completed NCT00789256 - Low Dose Melphalan and Bortezomib for AML and High-Risk MDS N/A
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Completed NCT01020539 - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia Phase 1
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Terminated NCT02203773 - Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) Phase 1